GENOME ANNOUNCEMENT
===================

Here, we report the draft genome sequences of the methicillin-resistant *Staphylococcus aureus* (MRSA) strains MM25, MM61, and MV8 ([Table 1](#tab1){ref-type="table"}). These strains, along with the heterogeneous vancomycin-intermediate *S. aureus* (hVISA) strain MM66 ([@B1]), were isolated from hospitals in Las Cruces, New Mexico ([@B2]). The SmaI chromosomal DNA pulsed-field gel electrophoresis patterns of MM61 and MM66 demonstrated that these strains are clonal ([@B2]).

###### 

Draft genome information

  Strain   Coverage (×)^*[a](#TF1-1){ref-type="table-fn"}*^   No. of scaffolds (≥1 kb)   Draft genome size (Mb)   No. of RAST predicted features   Accession no.
  -------- -------------------------------------------------- -------------------------- ------------------------ -------------------------------- --------------------------------
  MM25     621                                                57                         2.89                     2,734                            [CCCE000000000](CCCE000000000)
  MM61     614                                                78                         2.96                     2,815                            [CCCA000000000](CCCA000000000)
  MV8      686                                                81                         3.03                     2,816                            [CCCL000000000](CCCL000000000)

Based on a genome size estimate of 3 Mbp.

Genomic libraries were constructed using the Phusion Illumina genomic DNA library protocol (average insert size, 380 bp) and sequenced with the Illumina Genome Analyzer II 90-bp paired-end reads. The raw sequence reads were then screened for sequencing artifacts and ΦX contamination. *De novo* assemblies were generated using filtered sequence reads utilizing the ABySS version 1.3.7 assembler ([@B3]). The GapCloser version 1.12-r6 module from the Short Oligonucleotide Analysis Package (SOAP) ([http://soap.genomics.org.cn/](http://www.ccrbtyping.net/)) ([@B4]) was used to attempt to resolve the N-spacers introduced in the assembly scaffolding process. After the gap filling process, the percentage of gaps was \<0.03% per strain, and scaffolds ≥1 kb were retained in the final assembly. An assembly assessment for validation was performed by mapping high-quality Illumina reads back to the assembly using Burrows-Wheeler Aligner (BWA) ([@B5]). A high percentage of reads mapped uniquely to the assemblies in each strain (\>95% uniquely mapped back, with \>90% properly paired for all strains), validating the *de novo* assembly process. Gene prediction and annotation of final assemblies were carried out using RAST ([@B6]), incorporating the Glimmer algorithm ([@B7], [@B8]).

The G+C content of all strains (\~33%) was similar to that of sequenced *S. aureus* strains ([@B9]), as determined by GAEMR evaluation ([http://www.broadinstitute.org/software/gaemr/](http://www.ccrbtyping.net/)). Sequence analysis revealed that MM25 and MM61 are from multilocus sequence type 5 (ST-5) ([http://saureus.mlst.net/](http://www.ccrbtyping.net/)) and possess a staphylococcal chromosome cassette *mec* element type II (SCC*mec* II) (<http://www.ccrbtyping.net/>), while strain MV8 is from ST-8 and harbors SCC*mec* IV. Out of the 152 MRSA strains analyzed in Delgado et al. ([@B2]), 123 were resistant to ciprofloxacin, clindamycin, and erythromycin. The draft genomes of all three strains revealed the presence of *ermA*, which supports clindamycin and erythromycin resistance ([@B10]). Fluoroquinolone resistance in *S. aureus* is mediated by mutations in the genes encoding DNA gyrase (*gyrA*) or topoisomerase IV (*grlA*) subunits ([@B11][@B12][@B13]). MM25 and MM61 harbor *gyrA* and *grlA* mutations that lead to amino acid alterations in GyrA (S84L) and GrlA (S80F), respectively. MM25 also has another mutation in *grlA* leading to an alteration in GrlA (E84G). MM61 also harbors *tetM*, which encodes tetracycline resistance ([@B14]).

Vancomycin-intermediate *S. aureus* (VISA) strains, including hVISA, emerge *in vivo* or *in vitro* following vancomycin exposure, and these mutants often possess chromosomal mutation(s) that lead to altered cell wall metabolism ([@B15]). None of the three MRSA draft genomes contained the VISA-associated *graS* mutation previously found in MM66 and MM66 derivatives exhibiting altered vancomycin susceptibility ([@B1]). hVISA, VISA, and vancomycin-susceptible related strain sets (e.g., MM66, MM66 derivatives, and MM61) are routinely exploited to decipher mutations associated with *S. aureus* vancomycin-intermediate resistance mechanisms ([@B15]).

Nucleotide sequence accession numbers. {#h1}
--------------------------------------

These draft genome projects have been deposited at DDBL/EMBL/GenBank under the accession numbers described in [Table 1](#tab1){ref-type="table"}.
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